Wall Street brokerages expect Maximus, Inc. (NYSE:MMS) to post sales of $816.73 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Maximus’ earnings. The lowest sales estimate is $795.96 million and the highest is $851.10 million. Maximus posted sales of $818.14 million during the same quarter last year, which indicates a negative year-over-year growth rate of 0.2%. The firm is expected to issue its next earnings results on Thursday, May 6th.
According to Zacks, analysts expect that Maximus will report full year sales of $3.46 billion for the current financial year, with estimates ranging from $3.42 billion to $3.50 billion. For the next year, analysts expect that the business will report sales of $3.53 billion, with estimates ranging from $3.50 billion to $3.57 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Maximus.
Maximus (NYSE:MMS) last posted its earnings results on Thursday, February 4th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.09. Maximus had a net margin of 6.20% and a return on equity of 17.60%. The business had revenue of $945.60 million for the quarter, compared to analyst estimates of $846.46 million. During the same period in the prior year, the company posted $0.91 EPS. The company’s revenue for the quarter was up 15.6% on a year-over-year basis.
In other Maximus news, insider Thomas D. Romeo sold 5,529 shares of the firm’s stock in a transaction that occurred on Wednesday, December 9th. The shares were sold at an average price of $72.44, for a total value of $400,520.76. Following the transaction, the insider now directly owns 10,905 shares of the company’s stock, valued at approximately $789,958.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Vice Chairman Richard A. Montoni sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 10th. The stock was sold at an average price of $71.27, for a total transaction of $783,970.00. The disclosure for this sale can be found here. Insiders sold a total of 28,529 shares of company stock worth $2,033,131 over the last three months. Corporate insiders own 2.00% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its holdings in Maximus by 28.6% in the 4th quarter. JPMorgan Chase & Co. now owns 209,003 shares of the health services provider’s stock valued at $15,297,000 after purchasing an additional 46,460 shares during the last quarter. Truist Financial Corp acquired a new stake in Maximus in the 4th quarter valued at approximately $447,000. Voloridge Investment Management LLC increased its holdings in Maximus by 340.4% in the 4th quarter. Voloridge Investment Management LLC now owns 14,402 shares of the health services provider’s stock valued at $1,054,000 after purchasing an additional 11,132 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Maximus by 116.0% in the 4th quarter. Squarepoint Ops LLC now owns 7,763 shares of the health services provider’s stock valued at $568,000 after purchasing an additional 4,169 shares during the last quarter. Finally, Morgan Stanley increased its holdings in Maximus by 97.0% in the 4th quarter. Morgan Stanley now owns 173,662 shares of the health services provider’s stock valued at $12,711,000 after purchasing an additional 85,491 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.
Shares of MMS stock traded up $0.18 during mid-day trading on Thursday, hitting $83.31. 7,413 shares of the stock were exchanged, compared to its average volume of 383,444. The firm has a fifty day moving average of $78.59 and a 200 day moving average of $73.83. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Maximus has a 52-week low of $46.42 and a 52-week high of $84.73. The company has a market cap of $5.12 billion, a PE ratio of 24.45 and a beta of 0.84.
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 26th. Shareholders of record on Friday, February 12th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Thursday, February 11th. Maximus’s dividend payout ratio (DPR) is 33.04%.
Maximus, Inc provides business process services (BPS) to government health and human services programs worldwide. It operates through three segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers various BPS solutions, such as program administration, appeals and assessments, and related consulting works for U.S.
Recommended Story: How a Strangle Strategy is different from a Straddle Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.